ABBOTT LABORATORIES acquisition history

Exact Sciences is a leader in large and fast-growing cancer screening and precision oncology diagnostics, best known for the Cologuard colorectal cancer screening test and the Oncotype DX cancer recurrence assays. approximately $21 billion equity value (about $23 billion including net debt).

Abbott has repeatedly taken on the world's most challenging health issues and made a meaningful impact on the lives of people in areas such as diabetes, cardiovascular disease and infectious disease. With Exact Sciences, we will do the same in cancer.Robert B. Ford — Chairman and CEO, Abbott

With the legacy and deep expertise of the Exact Sciences team, we're ready to transform cancer care.Abbott management — Exact Sciences completion release

St. Jude Medical is a global medical device company with leading positions in cardiac rhythm management, atrial fibrillation, heart failure and neuromodulation. approximately $25 billion equity value ($46.75 cash + 0.8708 Abbott shares per share, ~$85/share; ~$30 billion total value including debt).

Bringing together these two great companies will create a premier medical device business and immediately advance Abbott's strategic and competitive position.Miles D. White — Chairman and CEO, Abbott

Alere is a global leader in point-of-care diagnostics, providing rapid tests across infectious disease, cardiometabolic and toxicology testing close to the patient. $51 per share, approximately $5.3 billion at close (originally announced at $56 per share / ~$5.8 billion equity value).

We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.Miles D. White — Chairman and CEO, Abbott

Our leading platforms and global presence in point-of-care diagnostics, combined with Abbott's broad portfolio of market-leading products, position the combined company for strong growth.Namal Nawana — President and CEO, Alere

CFR Pharmaceuticals is a Latin America-based branded generics pharmaceutical company with a broad portfolio of well-known, trusted products and a strong presence across the fast-growing region. approximately $2.9 billion.

By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of health care.Abbott — CFR completion news release

Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint. EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments.

Piramal's Healthcare Solutions business is a leading branded generics pharmaceutical operation in India with a broad product portfolio and extensive local distribution. $2.2 billion up-front plus $400 million annually for four years beginning in 2011 (approximately $3.72 billion total).

Advanced Medical Optics is a leader in eye care, holding the number one position in LASIK surgical devices, number two in the cataract surgical device market and number three in the contact lens care market. $22.00 per share, approximately $2.8 billion including debt.

Guidant's vascular intervention and endovascular solutions businesses, including coronary and peripheral stent and angioplasty product lines, acquired from Boston Scientific as a condition of Boston Scientific's acquisition of Guidant. approximately $4.1 billion (acquired from Boston Scientific in connection with its acquisition of Guidant).

Kos Pharmaceuticals is a specialty pharmaceutical company focused on cardiometabolic and respiratory products, including the Niaspan and Advicor lipid-management franchises. $78.00 per share in cash (approximately $3.7 billion).

BASF's pharmaceutical business, operated as Knoll Pharmaceuticals, including the global operations and an early-stage anti-inflammatory antibody (later commercialized by Abbott as HUMIRA). approximately $6.9 billion in cash.

Vysis is a genomic disease management company specializing in molecular cytogenetic and FISH-based diagnostic products for cancer and genetic disease. $30.50 per share in cash (approximately $355 million).

i-STAT is the handheld point-of-care platform at the core of Abbott's with-patient blood testing business. The prescription device runs a wide range of blood tests from just two or three drops of a sample and returns lab-quality results in a matter of minutes, letting clinicians test wherever the patient is rather than sending samples to a central lab. Abbott reports the technology is used across a large share of U.S. hospitals, from the ICU and operating room to radiology, and it anchors the company's Point of Care diagnostics franchise, later modernized as the i-STAT Alinity system. $15.35 per share in cash (approximately $392 million).

Facet Biotech is a biotechnology company with a portfolio of biologic drug candidates, including programs in multiple sclerosis and oncology and an antibody-engineering platform. $27.00 per share in cash (approximately $450 million; net of cash ~$722 million enterprise / ~$450M net).

Cardiovascular Systems, Inc. (CSI) makes an atherectomy system used in treating peripheral and coronary artery disease, adding complementary technologies to Abbott's portfolio of vascular device offerings. $851 million ($20.00 per common share).

On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI). CSI's atherectomy system, which is used in treating peripheral and coronary artery disease, adds complementary technologies to Abbott's portfolio of vascular device offerings.Abbott FY2023 10-K — Item 1 Business

Bigfoot Biomedical develops connected insulin-management solutions, furthering Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.

On September 22, 2023, Abbott completed the acquisition of Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott's efforts to develop connected solutions for making diabetes management more personal and precise.Abbott FY2023 10-K — Item 1 Business

Walk Vascular is a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots; its peripheral thrombectomy system has been incorporated into Abbott's existing endovascular portfolio.

In September 2021, Abbott acquired Walk Vascular, LLC (Walk Vascular), a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots. Walk Vascular's peripheral thrombectomy system has been incorporated into Abbott's existing endovascular portfolio.Abbott FY2023 10-K — financial statements note

IDEV Technologies, headquartered in Webster, Texas, is a privately held company developing next-generation devices for interventional radiologists, vascular surgeons and cardiologists, including the SUPERA Veritas self-expanding interwoven-nitinol stent for treating peripheral artery disease. Abbott acquired all outstanding equity to expand and complement its peripheral-vascular portfolio of guidewires, balloon catheters and stents.

Tendyne Holdings is a private medical-device company developing minimally invasive mitral valve replacement therapies; its Bioprosthetic Mitral Valve System is designed to be implanted in a beating heart without open-heart surgery. Abbott acquired the equity it did not already own to broaden its foundation in treatments for mitral valve disease.

Cephea Valve Technologies is a privately held medical-device company developing a less-invasive transcatheter mitral valve replacement delivered through a vein in the leg, avoiding open-heart surgery. Abbott had provided capital and secured a purchase option in 2015, and in January 2019 exercised that option to acquire the company, building on its structural-heart portfolio.